The first domestic pentavalent vaccine for the prevention of diphtheria, tetanus, whooping cough, hepatitis B and hemophilic infection on the principle of “5-in-1 shot” was approved by the Ministry of Health of the Russian Federation according to the results of clinical trials.
Read more
Relatox, the development of SPA Microgen, will become the only Russian analogue of the botulinum toxin type A products among available on the market used to treat chronic headaches.
Read more
The only manufacturer of the Russian botulinum toxin type A, SPA Microgen (Naсimbio, Rostec State Corporation) has started clinical trials to expand the indications for Relatox in the treatment of cervical dystonia in patients aged 18 to 65 years.
Read more
Bacteriophages of the Scientific and Production Association Microgen of the Naсimbio holding (Rostec State Corporation) are used to prevent outbreaks of infectious diseases in the affected with the showers areas of the Kuban. More than 3,000 products were delivered to the region on Sunday.
Read more
SPA Microgen, part of the Naсimbio holding (Rostec State Corporation), has developed a new Russian drug for the treatment of primary immunodeficiency diseases. The drug, called BioGam, successfully passed the preclinical and Phase 1 of clinical studies that confirmed its safety.
Read more
SPA Microgen of the Naсimbio holding (part of Rostec State Corporation), together with leading Russian research institutions in the field of influenza prevention, based on the Irkutsk branch, created a new Russian live vaccine against a potentially pandemic H7N9 avian influenza virus.
Read more
